



# UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: Box ISSUE FEE

ASSISTANT COMMISSIONER FOR PATENTS

WASHINGTON, D.C. 20231

## NOTICE OF ALLOWANCE AND ISSUE FEE DUE

12M2/1203

STEVEN F WEINSTOCK ABBOTT LABORATORIES D-377/AP6D 100 ABBOTT PARK ROAD ABBOTT PARK IL 60064-3500

APPLICA	TION NO.	FILING DATE	TOTAL CLAIMS	EXAM	MINER AND GROUP ART UNIT		DATE MAILED
	08/687,774	06/26/96	044	AULAKH,	С	1203	12/03/97
First Named Applicant	NORBECK,		DAN	IIEL W.		-	

TITLE OF ME

METHOD FOR IMPROVING PHARMACOKINETICS

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN. T	YPE SMAL	L ENTITY	FEE DUE	DATE DU	E
1 5778.US	3.01 <b>514</b> -3	365.000	U80	UTILITY	/ NO	<b>\$1</b> 320	0.00 03/	/03/98

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED.</u>

### **HOW TO RESPOND TO THIS NOTICE:**

- Review the SMALL ENTITY status shown above.
   If the SMALL ENTITY is shown as yes, verify your current SMALL ENTITY status:
  - A. If the status is changed, pay twice the amount of the FEE DUE shown and notify the Patent and Trademark Office of the change in status, or
  - B. If the status is the same, pay the FEE DUE shown above.
- If the SMALL ENTITY is shown as NO:
- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.
- II. Part B of this notice should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "6b" of Part B should be completed.
- III. All communications regarding this application must give application number and batch number.

  Please direct all communication prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.



# UNITED STATEL PARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FIRST NAMED APPLICANT

ATTORNEY DOCKET NO.

08/687,774

06/26/96

NORBECK

D 5778.US.01

12M2/1203 ·

STEVEN F WEINSTOCK ABBOTT LABORATORIES D-377/AP6D 100 ABBOTT PARK ROAD ABBOTT PARK IL 60064-3500

EXAMINER AULAKH, C PAPER NUMBER ART UNIT

1203

DATE MAILED:

12/03/97

This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS  $\_$ 

#### **NOTICE OF ALLOWABILITY**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or
previously mailed), a Notice of Allowance and Issue Fee Due or other appropriate communication will be mailed in due course.
This communication is responsive to takes 725.3, The second secon
The allowed claim(s) is/are
The drawings filed on are acceptable.
Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
All Some* None of the CERTIFIED copies of the priority documents have been
☐ received.
received in Application No. (Series Code/Serial Number)
<ul> <li>received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ul>
*Certified copies not received:
Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE <b>THREE MONTHS</b> FROM THE "DATE MAILED" of this Office action. Failure to timely comply will result in ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).
□ Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
Applicant MUST submit NEW FORMAL DRAWINGS
because the originally filed drawings were declared by applicant to be informal.
The state of the state of Design Control Provided Design DTO 040 etherhald besets on to Depart No.
including changes required by the Notice of Draftperson's Patent Drawing Review, PTO-948, attached hereto or to Paper No.
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
including changes required by the proposed drawing correction filed on, which has been approved
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
<ul> <li>☐ including changes required by the proposed drawing correction filed on, which has been approved by the examiner.</li> <li>☐ including changes required by the attached Examiner's Amendment/Comment.</li> <li>☐ Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings.</li> </ul>
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.  including changes required by the attached Examiner's Amendment/Comment.  Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson.
<ul> <li>including changes required by the proposed drawing correction filed on, which has been approved by the examiner.</li> <li>including changes required by the attached Examiner's Amendment/Comment.</li> <li>Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson.</li> <li>Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.</li> <li>Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER).</li> <li>If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF</li> </ul>
<ul> <li>including changes required by the proposed drawing correction filed on, which has been approved by the examiner.</li> <li>including changes required by the attached Examiner's Amendment/Comment.</li> <li>Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson.</li> <li>Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.</li> <li>Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER).</li> <li>If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included.</li> </ul>
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.  including changes required by the attached Examiner's Amendment/Comment.  Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson.  Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.  Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included.  Attachment(s)
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.  including changes required by the attached Examiner's Amendment/Comment.  Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson.  Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.  Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included.  Attachment(s)
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.  including changes required by the attached Examiner's Amendment/Comment.  Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson.  Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.  Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included.  Attachment(s)  Notice of References Cited, PTO-892  Information Disclosure Statement(s), PTO-1449, Paper No(s)
including changes required by the proposed drawing correction filed on
including changes required by the proposed drawing correction filled on
including changes required by the proposed drawing correction filed on
including changes required by the proposed drawing correction filed on

Serial Number: 08/687,774 Page 2

Art Unit:

# REASONS FOR ALLOWANCE

1. The following is an examiner's statement of reasons for allowance:

Claims 1-44 are allowed since the applicants arguments (paper no. 5, filed on August 25, 1997) were persuasive and therefore, rejection under 35 U.S.C. 103 (a) is withdrawn. The methods and compositions of instant claims are neither disclosed nor obvious over the prior art. In the prior art, Retroviral protease inhibitor combinations (WO 95/33464), and HIV protease inhibitor combinations (EP 0 691 345, WO 96/04913, cited on applicants form 1449) are disclosed which are closely related to the instant claims. However, these publications were published after the priority date of the instant application and therefore, can not be used as prior art references.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

2. Any inquiry concerning this communication should be directed to Chana Aulakh at (703) 305-4482.

C War Ing SPE 1203